Q-omics provides the consensus-scored TST profile across patient tissues and cancer cell-line models. TST expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TST is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, TST protein abundance shows 23,500 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight MESO, COAD, and UCEC as cancer lineages where TST shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TST — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TST survival associations across molecular data types. TST RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TST RNA expression–survival associations across cancer types. High TST expression shows unfavorable associations in UCS and THYM, but favorable associations in MESO, BLCA, KIRC and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TST RNA expression.
This table summarizes TST tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TST. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TST shows lower tumor expression in COAD, KIRP, KICH, HNSC, KIRC and BRCA. The COAD box plot shows higher TST RNA expression in normal versus tumor tissue (log2 FC = −1.384, t-test p < 0.001).
This table shows molecular features associated with TST in patient tissues and cancer cell lines. In patient samples, TST shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, TST RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
